Effects of Qigong on Type 2 Diabetic Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00885846|
Recruitment Status : Completed
First Posted : April 22, 2009
Results First Posted : April 22, 2009
Last Update Posted : November 16, 2015
Qigong therapy is a subtle energy-based methodology for preventing and healing diseases that has been practiced with remarkable results in China for about five thousand years. Recently, preliminary studies showed that Qigong exercises improve insulin resistance and glucose metabolism in people with type 2 diabetes. These studies suggest that Qigong therapy might be an effective and valuable complementary modality for treating type 2 diabetes. Type 2 diabetes is a chronic disease marked by abnormally high levels of sugar in the blood. Diabetes is a serious disease, which, if not controlled, can be life threatening.
The purpose of this project is to conduct a randomized, controlled pilot clinical trial to compare the effectiveness of Qigong therapy to mild exercise and conventional treatment in type 2 diabetes and to identify biological and psychological characteristics associated with subjects' responses to Qigong therapy.
Aim 1: To compare the effects on blood sugar and hemoglobin A1c (HbA1c) level between a Qigong therapy group and non-treated control group as well as between Qigong group and a progressive resistance training (PRT) group before, during and after and 12-week intervention.
Hypothesis 1: Both Qigong therapy and PRT will help type 2 diabetic patients reduce blood sugar levels to different degrees through improving insulin resistance. But the levels of reduction of blood sugar will be greater by Qigong therapy than by PRT due to enhanced insulin secretion.
Aim 2: To compare the effects on fasting C-peptide and insulin levels between a Qigong therapy group, a PRT group and a non-treated control group before and after the intervention.
Hypothesis 2: Qigong therapy will increase the endogenous insulin and C-peptide levels by restoring the functions of the pancreas, while PRT will not alter either insulin or C-peptide levels.
Aim 3: To compare the effects of Qigong therapy and PRT on blood cortisol levels and psychological stress levels before, during and after the intervention.
Hypothesis 3: Perceived stress and depression will be improved by Qigong therapy to a greater extent than by PRT, and blood cortisol levels will be reduced to a greater extent with Qigong therapy.
|Condition or disease||Intervention/treatment||Phase|
|Diabetes Mellitus, Type 2||Other: Qigong therapy Other: Progressive resistance training||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||32 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Pilot Study: The Effects of Qigong Therapy on Type 2 Diabetic Patients|
|Study Start Date :||June 2007|
|Actual Primary Completion Date :||January 2008|
|Actual Study Completion Date :||May 2008|
|Active Comparator: Qigong Therapy||
Other: Qigong therapy
For 12 weeks, subjects in Qigong therapy group are to follow a disciplined regular practice, 3 times a week for about 30 minutes, including once a week with a certified instructor to lead and check the correctness of their practice.
|Active Comparator: PRT||
Other: Progressive resistance training
For 12 weeks, subjects in the PRT group are to follow a disciplined regular practice, 3 times a week for about 30 minutes, including once a week with a certified instructor to lead and check the correctness of their practice.
|No Intervention: Control|
- Fasting Blood Glucose [ Time Frame: Week 0 (baseline) and week 12 (final) ]
- Fasting C-peptide [ Time Frame: weeks 0 and 12 ]
- Fasting Insulin [ Time Frame: weeks 0 and 12 ]
- Perceived Stress Scale (PSS) [ Time Frame: weeks 0 and 12 ]
- Beck's Depression Inventory (BDI) [ Time Frame: weeks 0 and 12 ]
- HOMA-IR Index [ Time Frame: weeks 0 and 12 ]
- Fasting Cortisol [ Time Frame: Weeks 0 and 12 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00885846
|United States, Washington|
|Bastyr University Research Center|
|Kenmore, Washington, United States, 98028-4966|
|Principal Investigator:||Guan-Cheng Sun, PhD||Bastyr University|
|Study Director:||Jennifer C Lovejoy, PhD||Bastyr University|
|Study Chair:||Ryan Bradley, ND||Bastyr University|